Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers

Emma Janet Castillo, Silvia Delgado-Aros, Michael Camilleri, Duane Burton, Debra Stephens, Robin O'Connor-Semmes, Ann Walker, Anne Shachoy-Clark, Alan R. Zinsmeister

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

CCK influences satiation and gastric and gall-bladder emptying. GI181771X is a novel oral CCK-1 agonist; its effects on gastric emptying of solids, accommodation, and postprandial symptoms are unclear. Effects of four dose levels of the oral CCK-1 agonist GI181771X and placebo on gastric functions and postprandial symptoms were compared in 61 healthy men and women in a randomized, gender-stratified, double-blind, double-dummy placebo-controlled, parallel group study. Effects of 0.1, 0.5, and 1.5 mg of oral solution and a 5.0-mg tablet of GI181771X on gastric emptying of solids by scintigraphy, gastric volume by 99mTc-single photon emission computed tomographic imaging, maximum tolerated volume of Ensure, and postprandial nausea, bloating, fullness, and pain were studied. On each of 3 study days, participants received their randomly assigned treatment. Adverse effects and safety were monitored. There were overall group effects of GI1S1771X on gastric emptying (P < 0.01) and fasting and postprandial volumes (P = 0.036 and 0.015, respectively). The 1.5-mg oral solution of GI181771X significantly delayed gastric emptying of solids (P < 0.01) and increased fasting (P = 0.035) gastric volumes without altering postprandial (P = 0.056) gastric volumes or postprandial symptoms relative to placebo. The effect of the 5.0-mg tablet on gastric emptying of solids did not reach significance (P = 0.052). Pharmacokinetic profiles showed the highest area under the curve over 4 h for the 1.5-mg solution and a similar area under the curve for the 0.5-mg solution and 5-mg tablet. Adverse effects were predominantly gastrointestinal and occurred in a minority of participants. GI181771X delays gastric emptying of solids and exhibits an acceptable safety profile in healthy participants. CCK-1 receptors can be modulated to increase fasting gastric volume.

Original languageEnglish (US)
Pages (from-to)G363-G369
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume287
Issue number2 50-2
DOIs
StatePublished - Aug 1 2004

Keywords

  • Accommodation
  • Fasting
  • Satiation
  • Single photon emission computed tomography

ASJC Scopus subject areas

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers'. Together they form a unique fingerprint.

  • Cite this

    Castillo, E. J., Delgado-Aros, S., Camilleri, M., Burton, D., Stephens, D., O'Connor-Semmes, R., Walker, A., Shachoy-Clark, A., & Zinsmeister, A. R. (2004). Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. American Journal of Physiology - Gastrointestinal and Liver Physiology, 287(2 50-2), G363-G369. https://doi.org/10.1152/ajpgi.00074.2004